Colacot brings over 25 years of quality leadership experience across the biopharmaceutical and medical device industriesNEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics ...

ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on ...

Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors$15 ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-s ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).

Dyne Therapeutics Inc.-5.60% $1.56B ...

Mirati Therapeutics’ hopes of an EU approval for its KRAS inhibitor Krazati in the EU have been thrown into disarray after the EMA’s human medicines committee rejected the drug as a lung ...